Over 25 companies advance 30+ myasthenia gravis drugs, reshaping treatment options.

More than 25 companies are actively developing over 30 drugs for myasthenia gravis, a chronic autoimmune disorder causing muscle weakness. Key therapies in late-stage trials include targeted biologics like Immunoglobulin G degraders and Complement factor B inhibitors, which promise improved treatment outcomes. Recent developments feature promising drugs such as Descartes-08 and Cemdisiran, with ongoing Phase III trials and regulatory progress in the US and EU. This expanding pipeline signals significant innovation and potential new treatment options for patients worldwide.